Compare UNTY & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | AGMB |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.5M | 652.5M |
| IPO Year | 2014 | 2024 |
| Metric | UNTY | AGMB |
|---|---|---|
| Price | $58.69 | $12.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $65.00 | $32.00 |
| AVG Volume (30 Days) | 40.3K | ★ 164.2K |
| Earning Date | 04-14-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 39.66 | N/A |
| EPS | ★ 2.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | $9.56 | $17.86 |
| P/E Ratio | $20.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.34 | $8.75 |
| 52 Week High | $62.50 | $17.82 |
| Indicator | UNTY | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 43.02 |
| Support Level | $57.36 | $11.79 |
| Resistance Level | $60.73 | $12.83 |
| Average True Range (ATR) | 1.19 | 1.38 |
| MACD | -0.07 | -0.29 |
| Stochastic Oscillator | 27.00 | 20.42 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.